Zenith Drugs share news, announcements and annual reports

NSE: ZENITHDRUGPharmaceuticals & Biotechnology

Zenith Drugs Limited · Face value ₹10 · Listed Feb 2024 · Issue price ₹79

₹37.00₹0.30 (0.80%)

Share price at the NSE close on 30 Oct 2026. Previous close ₹37.30.

30 Oct: open ₹37.30, high ₹37.30, low ₹37.00

52-week range of traded prices to 30 Oct 2026

₹33.30Low, 30 Mar 2026₹65.25High, 31 Oct 2025

Market cap: ₹63 Cr
P/E: 16.09
P/B: 0.87
Dividend yield: Nonein the last 12 months
ROE: 5.5%
Debt to equity: 0.75
Volume, NSE: 1,600100.0% delivered

Zenith Drugs disputes and clarifications

11 filed, newest first.

Feb 2026
- 5 Feb · Legal
  Exchange had sought clarification from Zenith Drugs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1.Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.
Jan 2026
- 13 Jan · Legal
  Exchange has sought clarification from Zenith Drugs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2025
- 3 Jul · Legal
  Exchange had sought clarification from Zenith Drugs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. Financial results submitted in XBRL with discrepancies The response of the Company is enclosed.
Jun 2025
- 25 Jun · Legal
  Exchange has sought clarification from Zenith Drugs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Jan 2025
- 6 Jan · Legal
  Exchange had sought clarification from Zenith Drugs Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed.
Dec 2024
- 11 Dec · Legal
  Exchange has sought clarification from Zenith Drugs Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Sep 2024
- 23 Sep · Legal
  Exchange had sought clarification from Zenith Drugs Limited with respect to announcement dated 31-Aug-2024, regarding resignation of Mr. Sandeep Bhardwaj as the Chief Financial Officer of the Company w.e.f. August 31, 2024. On basis of above the Company was required to provide following: 1. Resignation Letter as per sub-para 7C of Para A of Part A of Schedule III of SEBI Listing Regulations, 2015. The response of the Company is attached.
- 13 Sep · Legal
  Exchange has sought clarification from Zenith Drugs Limited with respect to announcement dated 31-Aug-2024, regarding resignation of Mr. Sandeep Bhardwaj as the Chief Financial Officer of the Company w.e.f. August 31, 2024. On basis of above the Company is required to provide following: 1. Resignation Letter as per sub-para 7C of Para A of Part A of Schedule III of SEBI Listing Regulations, 2015. The response of the Company is awaited.
Jul 2024
- 18 Jul · Legal
  Significant movement in price has been observed in Zenith Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Mar 2024
- 18 Mar · Legal
  Significant movement in price has been observed in Zenith Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Zenith Drugs Limited has submitted their response.
- 14 Mar · Legal
  Significant movement in price has been observed in Zenith Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

Zenith Drugs disputes and clarifications

Feb 2026

Jan 2026

Jul 2025

Jun 2025

Jan 2025

Dec 2024

Sep 2024

Jul 2024

Mar 2024